Double drugging of prolyl-tRNA synthetase provides a new paradigm for anti-infective drug development

Toxoplasmosis is caused by Toxoplasma gondii and in immunocompromised patients it may lead to seizures, encephalitis or death. The conserved enzyme prolyl-tRNA synthetase (PRS) is a validated druggable target in Toxoplasma gondii but the traditional ‘single target–single drug’ approach has its cavea...

Descripción completa

Detalles Bibliográficos
Autores principales: Manickam, Yogavel, Malhotra, Nipun, Mishra, Siddhartha, Babbar, Palak, Dusane, Abhishek, Laleu, Benoît, Bellini, Valeria, Hakimi, Mohamed-Ali, Bougdour, Alexandre, Sharma, Amit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004777/
https://www.ncbi.nlm.nih.gov/pubmed/35333915
http://dx.doi.org/10.1371/journal.ppat.1010363

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004777/
https://www.ncbi.nlm.nih.gov/pubmed/35333915
http://dx.doi.org/10.1371/journal.ppat.1010363

Ejemplares similares